Treatment Clinical Trials for Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 96

  • PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

    Background: Drugs known as PARP inhibitors are known to help stop tumor growth in patients with breast, ovarian cancers and many other cancers including prostate and pancreatic cancers. Many research studies done in animals and human cells have shown that these type of drugs can improve how well chemotherapy works. Standard chemotherapy can be too toxic to be combined with PARP inhibitors. In this study, we use a new form of chemotherapy called PLX038 to see if it can be safely combined with PARP inhibitors to shrink tumors. Objective: To find a safe combination of PLX038 and rucaparib, and to see if this mix will cause tumors to shrink. Eligibility: People age 18 and older with solid tumors, SCLC, or small cell cancer outside their lungs. Design: Participants will be screened with: Physical exam Blood tests Records of their diagnosis (or they will have a tumor biopsy) A review of their symptoms and medications A review of their ability to perform their normal activities Electrocardiograms to measure the electrical activity of the heart Computed tomography (CT) scans of the chest, abdomen, and pelvis. CT scans are a series of X-rays. Participants will get PLX038 by intravenous catheter on Day 1 of each cycle (1 cycle = 21 days). For this, a small plastic tube is put into an arm vein. They will take rucaparib twice daily by mouth on Days 3 to 19 of each cycle. They will keep a medicine diary. Participants may give a hair sample. They may have optional tumor biopsies. Screening tests are repeated throughout the study. About 30 days after treatment ends, participants will have a safety follow-up visit. They will give blood samples, talk about their health, and get a physical exam. Then they will be called or emailed every 6 months....
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • NIAGEN for the Alleviation of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

    The phase II trial studies how well NIAGEN works in reducing peripheral neuropathy caused by chemotherapy in cancer survivors who have completed their cancer treatment. NIAGEN is a nutritional supplement and type of vitamin B3. NIAGEN may help alleviate peripheral neuropathy that persists in patients who have completed cancer treatment.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Alisertib and Osimertinib for the Treatment of EGFR-Mutated Stage IV Lung Cancer

    This phase I / Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and / or bad, it has on EGFR-mutated lung cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Durvalumab and Tremelimumab in Combination with Platinum-based Chemotherapy for the Treatment of Patients with Untreated Extensive-Stage Small Cell Lung Cancer

    This phase I trial studies how well durvalumab and tremelimumab given in combination with platinum-based chemotherapy work in treating patients with untreated extensive-stage small cell lung cancer. Extensive-stage small cell lung cancer is associated with aggressive biology and poor outcomes. Each study drug, durvalumab and tremelimumab, targets a different signal that may be stopping the body's immune system from killing the cancer. Durvalumab targets a signal on tumor cells and tremelimumab targets a signal on immune cells. It is hoped that by blocking these signals, the immune cells will once again be able to prevent or slow down cancer growth. Chemotherapy drugs such as carboplatin and etoposide, work in work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The information learned from the combination of immune boosting drugs may be identified as not excessively toxic and may be studied further to determine the benefit of using these as a therapy for extensive-stage small cell lung cancer.
    Location: University of Nebraska Medical Center, Omaha, Nebraska

  • Rucaparib and Nivolumab in Treating Patients with Stage IV Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well rucaparib and nivolumab work in treating patients with stage IV small cell lung cancer that has spread outside of the lung in which it begins to spread to other parts of the body (extensive stage). Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if the combination of rucaparib and nivolumab will increase the length of time prior to the progression (worsening) of extensive stage lung cancer compared to rucaparib or nivolumab alone.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky

  • Durvalumab with or without Tremelimumab or Olaparib after Thoracic Radiation Therapy in Treating Patients with Extensive Stage-Small Cell Lung Cancer

    This phase I / Ib trial studies the side effects and how well durvalumab with or without tremelimumab or olaparib works after thoracic radiation therapy in treating patients with extensive stage-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if all / any of the combinations of study treatment following thoracic radiation therapy will improve 6-month progression-free survival compared with a similar historical control group.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients with Locally Advanced Lung Cancer

    This early phase I trial studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy and how well it works in treating patients with lung cancer that has spread to nearby tissues or lymph nodes (locally advanced). Photodynamic therapy consists of injecting a light sensitive drug called a photosensitizer, such as porfimer sodium, into the vein, waiting for it to accumulate in the tumor, and then activating it with a red laser light. Giving photodynamic therapy with porfimer sodium may reduce the tumor size in patients with lung cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

    BACKGROUND: - Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. - The inability to destroy residual SCLC cells despite initial chemosensitivity suggests the existence of a highly effective DNA damage response network. SCLC is also characterized by high DNA replication stress (RB1 inactivation, MYC and CCNE1 activation). - There is only one FDA approved treatment for patients with relapsed SCLC after first-line chemotherapy: topotecan, which inhibits religation of topoisomerase I-mediated single-strand DNA breaks leading to lethal double-strand DNA breaks. Temozolomide, an oral alkylating agent, which causes DNA damage by alkylating guanine at position O6 also has activity in relapsed SCLC, particularly for brain metastases. - Preliminary evidence indicates that disruption of the immune checkpoint PD-1 / PD-L1 pathway can yield responses in a subset of SCLC patients, but response rates (approximately equal to 10%) are lower than NSCLC and other tumors with comparable tumor mutational burden indicating additional immunosuppressive mechanisms at play in the SCLC tumor microenvironment. - M7824 is a bifunctional fusion protein consisting of an anti-programmed death ligand 1 (PDL1) antibody and the extracellular domain of transforming growth factor beta (TGF-beta) receptor type 2, a TGF-beta trap. - Safety data from the dose-escalation study in solid tumors as well as preliminary data from expansion cohorts show that M7824 has a safety profile similar to other checkpoint inhibiting compounds. - Combining immunotherapy, and chemotherapy could synergistically improve the anticancer activity of immunotherapy. Combination of chemotherapy with immunotherapy have improved outcomes in NSCLC and melanoma leading to FDA approvals of such combinations. - We hypothesize that increased DNA damage induced by topotecan and temozolomide will complement the anti-tumor activity of M7824, in recurrent SCLC. OBJECTIVE: - The primary objective of the trial is to determine the efficacy (using objective response rate) of M7824 plus topotecan or temozolomide in relapsed SCLC. ELIGIBILITY: - Subjects with histological or cytological confirmation of SCLC. - Subjects must be greater than or equal to 18 years of age and have a performance status (ECOG) less than or equal to 2. - Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment. - Subjects must have adequate organ function and measurable disease. DESIGN: - Arm A (M7824 monotherapy): Up to 10 patients may be treated with M7824 monotherapy to obtain safety and PK data, and a preliminary estimate of clinical responses to M7824 in SCLC. Patients with progressive disease on Arm A may then receive M7824 plus temozolomide as per description of treatment for Arm C. - Arm B (M7824 plus topotecan) and Arm C (M7824 plus temozolomide) will be administered in 3 and 4-week cycles respectively; these arms will have a safety run-in followed by efficacy analysis. Up to 10 patients with extrapulmonary small cell cancer will be enrolled in arm C to receive the combination of M7824 and temozolomide. - Optional tumor biopsies will be obtained at pre-treatment on C1D1 and C1D15 for Arm C; pre-treatment on C1D1 and C2D1 for arms A and B. - Every subject of each arm of the safety run-in will be observed for at least 7 days after first dose of M7824 before the subsequent subject can be treated. Subjects who are not evaluable for DLT will be replaced and not included into evaluation ARMS: - Arm A (3-week cycles): M7824 monotherapy 2400 mg every 3 weeks until disease progression or a criterion in Protocol is met. Patients with progressive disease on Arm A may then receive 1200 mg M7824 every 2 weeks plus temozolomide 200 mg / m^2 / day on days 1-5 every 4 weeks. - Arm B (3-week cycles): M7824 2400 mg plus topotecan 1 mg / m2 on days 1-5 every 3 weeks until disease progression or a criterion in Protocol is met. - Arm C (4-week cycles): M7824 1200 mg every 2 weeks plus temozolomide 200 mg / m2 / day on days 1-5 every 4 weeks until disease progression or a criterion in Protocol
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Vorolanib with Nivolumab or Pembrolizumab in Treating Patients with Solid Tumors or Small Cell Lung Cancer

    This phase Ib trial studies the best dose of vorolanib when given together with nivolumab or pembrolizumab in treating patients with solid tumors or small cell lung cancer. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving vorolanib together with nivolumab or pembrolizumab works better at treating solid tumors or small cell lung cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Ipilimumab, Nivolumab, and Ad.p53-DC in Treating Participants with Relapsed Small Cell Lung Cancer

    This phase II trial studies the side effects of ipilimumab, nivolumab, and Ad.p53-DC, and to see how well they work in treating participants with small cell lung cancer that has come back after previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Cancer vaccines, such as Ad.p53-DC, may help the body build an effective immune response to kill cancer cells by telling cells which targets to attack. Giving ipilimumab and nivolumab in combination with Ad.p53-DC, may kill more tumor cells in participants with relapsed small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Phase I / II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and / or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

    Background: - MEDI4736 is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well participants tolerate the combination of these drugs in treating advanced solid tumors, and in the phase 2 part of this study, researchers want to study if the combination treatments are effective in ovarian cancer. Objectives: - Phase 2 part of the study: To determine how effective this combination is in treating ovarian cancer. Eligibility: - Phase 2 part of the study: Adults age 18 or older with advanced or recurrent ovarian cancer that has no standard treatment. Design: - Participants will be screened with medical history, physical exam, and blood and urine tests. They will have CT or MRI scans. For these, they will lie in a machine that takes pictures of their bodies. - Phase 2 part of the study requests the participants to have tumor samples removed. - Participants will get MEDI4636 through an IV. A small plastic tube will be inserted into a vein. The drug will be given every 4 weeks until disease progression. - Participants will take olaparib or cediranib by mouth every day. - Every 28 days will be 1 cycle. For cycle 1, participants will have 2 study visits. All other cycles, they will have 1 visit. At these visits, they will repeat the screening procedures. - Patients will keep a drug and diarrhea diary. - Patients on cediranib will monitor their blood pressure and keep a blood pressure diary. - Participants who can become pregnant, or have a partner who can become pregnant, must practice an effective form of birth control. - After 12 cycles, participants will have 1-3 months of follow-up.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Sirolimus and Auranofin in Treating Patients with Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
    Location: 2 locations

  • Lurbinectedin, Nivolumab, and Ipilimumab for the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of lurbinectedin and how well it works in combination with nivolumab and ipilimumab in treating patients with small cell lung cancer that has come back (relapsed) or has not responded to treatment (refractory). Lurbinectedin may stop the growth of tumor cells, by binding to the DNA of tumor cells and blocking factors associated with cancer cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lurbinectedin with nivolumab and ipilimumab may help treat patients with small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • PF-07104091 as a Single Agent and in Combination Therapy

    To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and / or select the Recommended Phase 2 dose (RP2D) for PF 07104091 as a single agent in participants with small cell lung, non small cell lung ovarian and breast cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

    This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have progressed after 1 or 2 lines of therapies. The primary objectives of the study are to evaluate the overall response rate of subjects treated with CC-90011 in combination with nivolumab in three cohorts: - Cohort A: SCLC in ICI naïve subjects - Cohort B: SCLC in ICI progressor subjects - Cohort C: sqNSCLC in ICI progressor subjects Overall response rate is defined as the proportion of subjects in the treated population who had complete response (CR) or partial response (PR) as assessed by Investigator review per RECIST v1.1. In Cohort A, expected ORR for nivolumab monotherapy is 14% while target ORR is 30%. To achieve at least 80% power with one-sided type 1 error 0.1, 39 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 12 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 2 or more subjects responding, Cohort A will continue to enroll an additional 27 subjects. If 1 or less subjects respond in stage 1, Cohort A will stop for futility. In Cohort B and C, expected ORR for nivolumab monotherapy is 5% while target ORR is 15%. To achieve at least 80% power with one-sided type 1 error 0.1, 48 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 14 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 1 or more subjects responding, Cohort B and C will continue to enroll an additional 34 subjects each. If 0 subjects respond in stage 1, Cohort B and C will stop for futility.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

    This first-in-human (FIH) trial aims to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a TLR7 agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors.
    Location: Northwestern University, Chicago, Illinois

  • Abemaciclib for the Treatment of Rb Wild-Type Refractory or Relapsed Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well abemaciclib works for the treatment of Rb wild-type extensive stage small cell lung cancer that does not respond to treatment (refractory) or has come back (relapsed). Abemaciclib may shrink lung cancer tumors in the body and stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Niraparib, Temozolomide and Atezolizumab in Treating Patients with Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer with a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

    This phase Ib / II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage small cell lung cancer with a complete or partial response to platinum-based first-line chemotherapy. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide, niraparib and atezolizumab may work better in treating patients with advanced solid tumors and extensive-stage small cell lung cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Nivolumab and Temozolomide in Treating Patients with Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

    This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Ipilimumab and Nivolumab in Treating Patients with Recurrent Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work in treating patients with extensive stage small cell lung cancer that has come back. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Abexinostat and Pembrolizumab in Treating Patients with MSI-High Locally Advanced or Metastatic Solid Tumors

    This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating patients with microsatellite instability (MSI) solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating patients with solid tumors.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline

    This phase I / II trial studies the best dose and side effects of stereotactic radiosurgery intreating participants whose cancer cells have spread to the brain from other organs in the body and studying their neurocognitive decline. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Stereotactic Radiosurgery followed by Tumor Treating Fields Therapy in Treating Participants with Small Cell Lung Cancer with Brain Metastases

    This trial studies how well stereotactic radiotherapy followed by tumor treating fields therapy work in treating participants with small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Given stereotactic radiosurgery and tumor treating fields therapy may help to reduce the chances of cancers coming back in other parts of your brain that are not being treated with stereotactic radiosurgery.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • PEN-866 in Patients With Advanced Solid Malignancies

    Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1 / 2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

    This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.
    Location: Hackensack University Medical Center, Hackensack, New Jersey